US2003195165A1PendingUtilityA1
Method for obtaining and using a combination of a purine and a nitrogen monoxide donor for preventing or treating sexual dysfunction
Priority: Dec 2, 1998Filed: Dec 13, 2002Published: Oct 16, 2003
Est. expiryDec 2, 2018(expired)· nominal 20-yr term from priority
Inventors:Philippe Gorny
A61P 15/10A61P 15/08A61K 9/0095A61K 33/00A61K 45/06A61P 15/00A61K 31/52A61K 31/70
39
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Abstract of Disclosure A method for using, in combination, a purine and a nitric oxide donor as active ingredients in the preparation of a drug for preventing or treating disorders of physiological and/or anatomical response to sexual stimulation in human beings.
Claims
exact text as granted — not AI-modifiedClaims
1. A method of treating a human being having or suspected of having a sexual dysfunction or a disorder of physiological and/or anatomical response to sexual stimulation, comprising:
administering to a human being having or suspected of having a sexual dysfunction or a disorder of physiological and/or anatomical response to sexual stimulation a purine and a nitric oxide donor agent, wherein said human being is not administered adenosine and linsidomine in combination.
2. The method of claim 1 , wherein said nitric oxide donor agent contains no linsidomine.
3. The method of claim 1 , wherein said purine contains no adenosine.
4. The method of claim 1 , wherein said purine is at least one member selected from the group consisting of adenine, adenosine, AMP, ADP and ATP.
5. The method of claim 4 , wherein said purine is adenosine and said nitric oxide donor agent contains no linsidomine.
6. The method of claim 1 , wherein said purine is at least one member selected from the group consisting of adenine, AMP, ADP and ATP.
7. The method of claim 1 , wherein said nitric oxide donor agent is at least one member selected from the group consisting of arginine, sodium nitroprussiate, organic nitrates, organic nitrites, thionitrites, molsidomine and pharmaceutically acceptable salts thereof.
8. The method of claim 1 , wherein said nitric oxide donor agent is arginine.
9. The method of claim 1 , wherein said purine and said nitric oxide donor agent are administered in the form of a capsule, gel capsule, drinkable solution or emulsion, granule, gel, cream, powder, lozenge, tablet, ointment, transdermal device, vaginal suppository, suppository, or solution.
10. The method of claim 9 , wherein said purine and said nitric oxide donor agent are administered by injection, by intranasal administration or by pulmonary administration.
11. The method of claim 1 , wherein said purine and said nitric oxide donor agent are administered in a single pharmaceutical form containing said purine and said nitric oxide donor agent.
12. The method of claim 1 , wherein said purine and said nitric oxide donor agent are administered in separate pharmaceutical forms, each pharmaceutical form containing one of said purine and said nitric oxide donor agent.
13. The method of claim 1 , wherein said purine is present in an amount of 30 to 150 mg per one or two doses.
14. The method of claim 1 , wherein said nitric oxide donor agent is arginine and said arginine is present in an amount of 1 to 8 g per one or two doses, calculated as the weight of arginine in free base form.
15. The method of claim 1 , wherein said nitric oxide donor agent is arginine and said arginine is present in an amount of 1.5 to 3 g per one or two doses, calculated as the weight of arginine in free base form.
16. The method of claim 1 , wherein said purine is AMP and said AMP is present in an amount of 30 to 150 mg per one or two doses.
17. The method of claim 1 , wherein said purine is AMP and said AMP is present in an amount of 50 to 100 mg per one or two doses.
18. The method of claim 1 , wherein said purine is AMP or ATP.
19. The method of claim 1 , wherein said purine is AMP or ATP and said nitric oxide donor agent is arginine.
20. The method of claim 1 , wherein said purine and said nitric oxide donor agent are a single compound having both purine and nitric oxide donor agent activities.
21. The method of claim 1 , wherein said human being is a man.
22. The method of claim 1 , wherein said human being is a woman.
23. A method of at least one of enhancing sexual desire, enhancing sexual pleasure, increasing sexual capacity and increasing sexual stimulation in human beings, comprising:
administering to a human being not suffering from a sexual dysfunction a purine and a nitric oxide donor agent, wherein said human being desires to enhance his or her sexual desire and/or sexual pleasure by administration of said purine and said nitric oxide donor agent, and wherein said human being is not administered adenosine and linsidomine in combination.
24. The method of claim 23 , wherein said nitric oxide donor agent contains no linsidomine.
25. The method of claim 23 , wherein said purine contains no adenosine.
26. The method of claim 23 , wherein said purine is at least one member selected from the group consisting of adenine, adenosine, AMP, ADP and ATP.
27. The method of claim 26 , wherein said purine is adenosine and said nitric oxide donor agent contains no linsidomine.
28. The method of claim 23 , wherein said purine is at least one member selected from the group consisting of adenine, AMP, ADP and ATP.
29. The method of claim 23 , wherein said nitric oxide donor agent is at least one member selected from the group consisting of arginine, sodium nitroprussiate, organic nitrates, organice nitrites, thionitrites, molsidomine and pharmaceutically acceptable salts thereof.
30. The method of claim 23 , wherein said nitric oxide donor agent is arginine.
31. The method of claim 23 , wherein said composition is in the form of a capsule, gel capsule, drinkable solution or emulsion, granule, gel, cream, powder, lozenge, tablet, ointment, transdermal device, vaginal suppository, suppository, or solution.
32. The method of claim 31 , wherein said composition is administered by injection, by intranasal administration or by pulmonary administration.
33. The method of claim 23 , wherein said purine and said nitric oxide donor agent are administered in a single composition.
34. The method of claim 23 , wherein said purine and said nitric oxide donor agent are administered in separate compositions, each composition containing one of said purine and said nitric oxide donor agent.
35. The method of claim 23 , wherein said purine is present in an amount of 30 to 150 mg per one or two doses.
36. The method of claim 23 , wherein said nitric oxide donor agent is arginine and said arginine is present in an amount of 1 to 8 g per one or two doses, calculated as the weight of arginine in free base form.
37. The method of claim 23 , wherein said nitric oxide donor agent is arginine and said arginine is present in an amount of 1.5 to 3 g per one or two doses, calculated as the weight of arginine in free base form.
38. The method of claim 23 , wherein said purine is AMP and said AMP is present in an amount of 30 to 150 mg per one or two doses.
39. The method of claim 23 , wherein said purine is AMP and said AMP is present in an amount of 50 to 100 mg per one or two doses.
40. The method of claim 23 , wherein said purine is AMP or ATP.
41. The method of claim 23 , wherein said purine is AMP or ATP and said nitric oxide donor agent is arginine.
42. The method of claim 23 , wherein said purine and said nitric oxide donor agent are a single compound having both purine and nitric oxide donor agent activities.
43. The method of claim 23 , wherein said human being is a man.
44. The method of claim 23 , wherein said human being is a woman.Join the waitlist — get patent alerts
Track US2003195165A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.